TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC
Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.
EP: 1.First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer
EP: 2.The Role of CTLA-4 Inhibitors in NSCLC
EP: 3.NSCLC: PD-L1 Expression and Treatment Decision-Making
EP: 4.TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC
EP: 5.Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC
EP: 6.EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC
EP: 7.TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC
EP: 8.A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC
EP: 9.First-Line Treatment for EGFR-Mutant Advanced Lung Cancer
EP: 10.FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC
EP: 11.MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC
EP: 12.Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond
EP: 13.MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond
EP: 14.Antibody-Drug Conjugates in EGFR-Mutant NSCLC
EP: 15.Clinical Pearls and Future Perspectives in Advanced NSCLC
This is a synopsis of a Peer Exchange video series featuring Benjamin P. Levy, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Solange Peters, MD, PhD, of University Hospital of Lausanne; Joshua K. Sabari, MD, of NYU Langone’s Perlmutter Cancer Center; Edward B. Garon, MD, MS, of UCLA Jonsson Comprehensive Cancer Center; and Marina Chiara Garassino, MD, of University of Chicago Medicine Comprehensive Cancer Center.
Dr Levy notes that while immunotherapy has improved first-line NSCLC [non–small cell lung cancer] outcomes, there remains only 1 approved second-line regimen: docetaxel with or without ramucirumab. Many trials have tried unsuccessfully to outperform docetaxel. Dr Peters concurs, stating recent failed trials with various immunotherapies and chemotherapies highlight docetaxel’s ongoing role as the second-line standard of care.
They discuss promising data from an abstract of the TROPION-Lung01 trial comparing the antibody-drug conjugate datopotamab deruxtecan to docetaxel in previously treated patients with NSCLC. Dr Peters explains the trial showed statistically significant improvement in progression-free survival from 3.7 to 4.4 months overall, and 3.7 to 5.6 months in the pre-planned non-squamous subgroup analysis. Response rate also nearly doubled from 13% to 26%. Toxicity profiles differ, but serious adverse events were lower with datopotamab deruxtecan.
In summary, Dr Peters feels these efficacy and toxicity findings support datopotamab deruxtecan as a new competitor to docetaxel in the second-line NSCLC setting that is likely to be adopted into clinical practice. Dr Levy agrees this is an important advance for patients progressing after first-line therapy.
*Video synopsis is AI-generated and reviewed by OncLive editorial staff.
